Videos for HCPs

In this section, the faculty members provide short video segments discussing key aspects of care in melanoma, with a particular emphasis on side-effect management and patient education.

Health Care Provider Videos

In this video, Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, discusses the management of skin toxicities associated with use of immune checkpoint inhibitors.

In this video, Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, reviews the differential diagnosis and management of confusion in patients receiving immune checkpoint inhibitors.

In this video, Brianna Hoffner, MSN, AOCNP, RN, reviews the differential diagnosis and management of myalgia in patients receiving immune checkpoint inhibitors.

In this video, Brianna Hoffner, MSN, AOCNP, RN, discusses the risk-benefit discussion in patients receiving adjuvant immunotherapy for high-risk melanoma.

In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, explains how he discusses the benefits and risks of adjuvant immune checkpoint inhibitor therapy with patients.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses the financial considerations involved with the adjuvant therapy decision.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses how to counsel patients regarding fertility issues when considering adjuvant therapy.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses triage and management of pyrexia in patients receiving BRAF/MEK inhibitor therapy.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses the management of cardiac AEs associated with BRAF/MEK inhibitor therapy.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses the steps to recognize and manage ocular AEs associated with BRAF/MEK inhibitor therapy.

In this video, Lisa A. Kottschade, APRN, MSN, CNP, of the Mayo Clinic, discusses the data leading to the approval of adjuvant therapy with BRAF/MEK inhibitors in melanoma.